Doripenem Versus Bacteria: An Emerging Battleground

REFERENCES

• Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096.
   Google Scholar
• Davies TA, Shang W, Bush K et al. Activity of doripenem and comparator 13-lactams against US clinical isolates of Strep-tococcus pneumoniae with defined mutations in the penicillin binding domains of pbpla, pbp2b and pbp2x. J Antimicrob Chemother 2008; 61: 751–753.
   Google Scholar
• Poulakou G, Giamarellou H. Doripenem: an expected arrival in the treatment of infections caused by multidrug resistant G negative pathogens. Expert Opin Investig Drugs 2008; 17: 749–771.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay Let al. Comparative review of the carbapenems. Drugs 2007; 67: 1027–1052.
   PubMed Web of Science ®Google Scholar
• Iso Y, Irie T, Nishino Y et al. A novel 113-methylcar-bapenem antibiotic, S-4661: synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-113-methlycarbapenems. J Antibiot 1996; 49: 199–209.
   Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ et al. Doripenem (S-4661), a novel carbapenem: Comparative activity against con-temporary pathogens including bactericidal action and prelimi-nary in vitro methods evaluation. J Antimicrob Chemother 2004; 54: 144–154.
   Google Scholar
• Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem Pharmacol 2006; 71: 1085–1095.
   PubMed Web of Science ®Google Scholar
• Kim A, Banevicius MA, Nicolau DP. In vivo pharmacody-namic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008; 52: 2497–2502.
   PubMed Web of Science ®Google Scholar
• Hori T, Nakano M, Kimura Y et al. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intra-venously administered to laboratory animals. In Vivo 2006; 20: 91–96.
   Google Scholar
• Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG. Urinary bactericidal activity of doripenem versus levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother. 2009; [in press].
   Google Scholar
• Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo anti-bacterial activities of 5-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42: 94–99.
   Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (5-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-3140.
   Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (5-4661): A global surveillance report. Clin Micro-biol Infect 2005; 11: 974–984.
   PubMed Web of Science ®Google Scholar
• Ge Y, Wikler MA, Sahm DF et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 1384–1396.
   PubMed Web of Science ®Google Scholar
• Doribax [Package insert]. Raritan NJ: Ortho-McNeil Phar-maceutical Inc; 2007.
   Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various13-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71–74.
   PubMed Web of Science ®Google Scholar
• Hoffmann H, Stiirenburg E, Heesemann J et al. Preva-lence of extended-spectrum 13-lactamases in isolates of the En-terobacter cloacae complex from German hospitals. Clin Microbiol Infect 2006; 12: 322–330.
   Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 1313–1319.
   PubMed Web of Science ®Google Scholar
• Datta N, Kontomichalou P. Penicillinase synthesis con-trolled by infectious R factors in Enterobacteriaceae. Nature 1965; 208: 239–241.
   PubMed Web of Science ®Google Scholar
• Shakil S, Akram M, Khan AU. Tigecycline: a critical up-date. J Chemother 2008; 20: 411–419.
   PubMed Web of Science ®Google Scholar
• Naber K, Redman R, Kotey P, et al. Intravenous therapy with doripenem vs. levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract in-fection and pyelonephritis. In: Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Mu-nich, Germany, Apr 1-4 2007. [abstract 1733_331].
   Google Scholar
• Solomkin J, Umeh O, Jiang J, et al. Doripenem versus meropenem with an option for oral stepdown therapy in the treatment of complicated intra-abdominal infections. [poster] Presented at the 47th Annual Interscience Conference on Antimi-crobial Agents and Chemotherapy (ICAAC), Chicago, Illinois, September 17-20, 2007.
   Google Scholar
• Lucasti C, Jasovich A, Umeh 0 et al. Treatment of com-plicated intra-abdominal infections: doripenem versus meropenem. In: 17th European Congress of Clinical Microbiol-ogy and Infectious Diseases ICC, Munich, Germany, 31 Mar - 04 Apr 2007. Abstract 1733-332.
   Google Scholar
• Réa-Net° A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosoco-mial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-2126.
   Google Scholar
• Nakajima Y, Mizobuchi M, Nakamura M et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004; 32: 1383–1391.
   PubMed Web of Science ®Google Scholar
• Merchant S, Gast C, Nathwani D et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008; 30: 717–733.
   Google Scholar